Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular EDEMA

Retina

Volumn 33, Issue 4, 2013, Pages 740-747

  Shimura, Masahiko ^a,c   Yasuda, Kanako ^a   Yasuda, Masayuki ^b   Nakazawa, Toru ^b  

^a NTT East Tohoku Hospital   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CASE STUDY; DIABETIC MACULAR EDEMA; DIFFUSE DIABETIC MACULAR EDEMA; DRUG EFFICACY; EYE DISEASE; HUMAN; IMAGING AND DISPLAY; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REMISSION; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA CYSTOID EDEMA; RETINAL THICKNESS; SINGLE DRUG DOSE; SPONGE LIKE DIFFUSE RETINAL THICKENING; TREATMENT DURATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD GLUCOSE; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84875951355     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31826b6763     Document Type: Article

References (34)

1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema, report #1.Arch Ophthalmol 1985;103:1796-1806
2. Antcliff RJ, Marshall J.The pathogenesis of edema in diabetic maculopathy.Semin Ophthalmol 1999;14:223-232
3. Ma JX, Zhang SX, Wang JJ.Down-regulation of angiogenic inhibitors: A potential pathogenic mechanism for diabetic complications.Curr Diabetes Rev 2005;1:183-196
4. Montero JA, Ruiz-Moreno JM, De La Vega C.Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.Eur J Ophthalmol 2008; 18:469-472
5. Shimura M, Yasuda K, Nakazawa T, et al.Visual outcome after intravitreal triamcinolone acetonide depends on opticalcoherence tomographic patterns in patients with diffuse diabetic macular edema.Retina 2011;31:748-754
6. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al.Primary intravitreal bevacizumab (Avastin) for diabetic macular edema.Ophthalmology 2007;114:743-750
7. Haritoglou C, Kook D, Neubauer A, et al.Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema.Retina 2006;26:999-1005
8. Otani T, Kishi S, Maruyama Y.Patterns of diabetic macular edema with optical coherence tomography.Am J Ophthalmol 1999;127:688-693
9. Kim BY, Smith SD, Kaiser PK.Optical coherence tomographic patterns of diabetic macular edema.Am J Ophthalmol 2006;142:405-412
10. Arevalo JF, Sanchez JG, Wu L, et al.Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months.Ophthalmology 2009;116:1488-1497, 1497.e1
11. Goyal S, Lavalley M, Subramanian ML.Meta-Analysis and review on the effect of bevacizumab in diabetic macular edema.Graefes Arch Clin Exp Ophthalmol 2011;249:15-27
12. Kim M, Lee P, Kim Y, et al.Effect of intravitreal bevacizumab injection based on optical coherence tomography patterns of diabetic macular edema.Ophthalmologica 2011;226:138-144
13. Antonetti DA, Barber AJ, Khin S, et al.Vascular permeability in experimental diabetes is associated with reduced endothelial occlusion content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells.Penn State Retina Research Group.Diabetes 1998;47:1953-1959
14. Aiello LP, Avery RL, Arrigg PG, et al.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.N Eng J Med 1994;331: 1480-1487
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z.Vascular endothelial growth factor (VEGF) and its receptors.FASEB J 1999;13:9-22
16. Grant MB, Afzal A, Spoerri P, et al.The role of growth factors in the pathogenesis of diabetic retinopathy.Expert Opin Investig Drugs 2004;13:1275-1293
17. Gardner TW, Antonetti DA, Barber AJ, et al.Diabetic retinopathy: More than meets the eye.Surv Ophthalmol 2002;47: S253-S262
18. Plate KH, Breier G, Weich HA, Rosau W.Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.Nature 1992;359:845-848
19. Shweiki D, Itin A, Soffer D, Keshet E.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.Nature 1992;359:843-845
20. Otani T, Kishi S.Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema.Ophthalmology 2007;114:104-107
21. Otani T, Kishi S.Tomographic assessment of vitreous surgery for diabetic macular edema.Am J Ophthalmol 2000;129:487-494
22. Weinberger D, Fink-Cohen S, Gaton DD, et al.Non-retinovascular leakage in diabetic maculopathy.Br J Ophthalmol 1995;79: 728-731
23. Kang SW, Park CY, Ham DI.The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema.Am J Ophthalmol 2004;137:313-322
24. Ferris FL, Patz A.Macular edema: A complication of diabetic retinopathy.Surv Ophthalmol 1984;28:452-461
25. Grimes PA, Laties AM.Early morphological alteration of the pigment epithelium in streptozotocin-induced diabetes: Increased surface area of the basal cell membrane.Exp Eye Res 1980;30: 631-639
26. Kirber WM, Nichols CW, Grimes PA, et al.A permeability defect of the retinal pigment epithelium.Occurrence in early streptozotocin diabetes.Arch Ophthalmol 1980;98:725-728
27. Spaide RE, Yannuzzi L, eds.Manifestation and Pathophysiology of Serous Detachment of the Retinal Pigment Epithelium and Retina.New York, NY: Oxford University Press; 1998: 439-455
28. Diabetic Retinopathy Clinical Research Network.A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.Ophthalmology 2007;114:1860-1867
29. Soheilian M, Ramezani A, Yaseri M, et al.Initial macular thickness and response to treatment in diabetic macular edema.Retina 2011;31:1564-1573
30. Shimura M, Nakazawa T, Yasuda K, et al.Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.Am J Ophthalmol 2008;145:854-861
31. Paccola L, Costa RA, Folgosa MS, et al.Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).Br J Ophthalmol 2008;92: 76-80
32. Romeo-Aroca P.Managing diabetic macular edema: The leading cause of diabetes blindness.World J Diabetes 2011;2:98-104
33. Klein R, Klein BE, Moss SE, Cruickshanks KJ.The Wisconsin Epidemiologic Study of Diabetic Retinopathy.XV.The longterm incidence of macular edema.Ophthalmology 1995;102: 7-16
34. Klein R, Moss SE, Klein BE, et al.The Wisconsin epidemiologic study of diabetic retinopathy XI.The incidence of macular edema.Ophthalmology 1989;96:1501-1510